Paper41006824
Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease.
Diaz LA and 29 others. Nat Rev Gastroenterol Hepatol, 2025. Cited by 26 papers, by iCite.
Cite this record
ConductScience Library. Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease. Papers, record 41006824. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41006824
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Clinical Trials as Topic | Major topic |
| Research Design | Major topic |
| Liver Diseases, Alcoholic | Major topic |
| Humans | |
| Biomarkers | |
| Alcohol Drinking | |
| Endpoint Determination |
Source PubMed
References228
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30658728 | Non-invasive diagnosis and biomarkers in alcohol-related liver disease. | J Hepatol | 2019 | https://conductscience.org/library/papers/30658728 | PubMed |
| 2 | 34027340 | Genetic predisposition similarities between NASH and ASH: Identification of new therapeutic targets. | JHEP Rep | 2021 | https://conductscience.org/library/papers/34027340 | PubMed |
| 3 | 11172192 | Liver biopsy. | N Engl J Med | 2001 | https://conductscience.org/library/papers/11172192 | PubMed |
| 4 | 24848614 | Validation of blood phosphatidylethanol as an alcohol consumption biomarker in patients with chronic liver disease. | Alcohol Clin Exp Res | 2014 | https://conductscience.org/library/papers/24848614 | PubMed |
| 5 | 32125254 | Liver Stiffness Measured with Two-dimensional Shear-Wave Elastography Is Predictive of Liver-related Events in Patients with Chronic Liver Disease Due to Hepatis B Viral Infection. | Radiology | 2020 | https://conductscience.org/library/papers/32125254 | PubMed |
| 6 | 31169533 | Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease. | Am J Gastroenterol | 2019 | https://conductscience.org/library/papers/31169533 | PubMed |
| 7 | 38881524 | Relationship between alcohol intake based on daily smartphone-reported consumption and PEth concentrations in healthy volunteers. | Alcohol Alcohol | 2024 | https://conductscience.org/library/papers/38881524 | PubMed |
| 8 | 37236193 | The enteric nervous system relays psychological stress to intestinal inflammation. | Cell | 2023 | https://conductscience.org/library/papers/37236193 | PubMed |
| 9 | 38851997 | EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). | J Hepatol | 2024 | https://conductscience.org/library/papers/38851997 | PubMed |
| 10 | 30458263 | Randomized trial seeking to induce the Hawthorne effect found no evidence for any effect on self-reported alcohol consumption online. | J Clin Epidemiol | 2019 | https://conductscience.org/library/papers/30458263 | PubMed |
| 11 | 34626833 | Clinical Utility of Magnetic Resonance Imaging Biomarkers for Identifying Nonalcoholic Steatohepatitis Patients at High Risk of Progression: A Multicenter Pooled Data and Meta-Analysis. | Clin Gastroenterol Hepatol | 2022 | https://conductscience.org/library/papers/34626833 | PubMed |
| 12 | 34168277 | Performance of non-invasive fibrosis scores in non-alcoholic fatty liver disease with and without morbid obesity. | Int J Obes (Lond) | 2021 | https://conductscience.org/library/papers/34168277 | PubMed |
| 13 | 37992972 | Association between public health policies on alcohol and worldwide cancer, liver disease and cardiovascular disease outcomes. | J Hepatol | 2024 | https://conductscience.org/library/papers/37992972 | PubMed |
| 14 | 35120736 | Baveno VII - Renewing consensus in portal hypertension. | J Hepatol | 2022 | https://conductscience.org/library/papers/35120736 | PubMed |
| 15 | 35843374 | Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design. | J Hepatol | 2022 | https://conductscience.org/library/papers/35843374 | PubMed |
| 16 | 25557690 | Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop. | Hepatology | 2015 | https://conductscience.org/library/papers/25557690 | PubMed |
| 17 | 38560775 | Liver stiffness predicts progression to liver-related events in patients with chronic liver disease - A cohort study of 14 414 patients. | Liver Int | 2024 | https://conductscience.org/library/papers/38560775 | PubMed |
| 18 | 38702474 | A physiologically-based digital twin for alcohol consumption-predicting real-life drinking responses and long-term plasma PEth. | NPJ Digit Med | 2024 | https://conductscience.org/library/papers/38702474 | PubMed |
| 19 | 32097176 | The utility of liver biopsy in 2020. | Curr Opin Gastroenterol | 2020 | https://conductscience.org/library/papers/32097176 | PubMed |
| 20 | 36881347 | Bariatric Surgery Is Associated with Alcohol-Related Liver Disease and Psychiatric Disorders Associated with AUD. | Obes Surg | 2023 | https://conductscience.org/library/papers/36881347 | PubMed |
Cited by17
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 26 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42939612 | Glycine Insufficiency as a Metabolic Vulnerability in MASLD: Implications for Precision Nutrition. | Curr Issues Mol Biol | 2026 | https://conductscience.org/library/papers/42939612 | PubMed |
| 42882113 | Physical Activity and Mediterranean Diet Adherence in Patients with Metabolic Syndrome and Alcohol-Related Liver Disease: A 12-Month Prospective Study. | J Clin Med | 2026 | https://conductscience.org/library/papers/42882113 | PubMed |
| 42783733 | MetALD Molecular Signatures: What We Know, What We Lack, and How to Move Forward Through Integrated Multi-Omics. | Metabolites | 2026 | https://conductscience.org/library/papers/42783733 | PubMed |
| 42732486 | Noninvasive surrogate endpoints in MASH trials: current perspectives and challenges. | Hepatol Int | 2026 | https://conductscience.org/library/papers/42732486 | PubMed |
| 42706034 | [Considerations on clinical trial issues related to new drug development for metabolic and alcohol-associated liver disease and fatty liver disease]. | Zhonghua Gan Zang Bing Za Zhi | 2026 | https://conductscience.org/library/papers/42706034 | PubMed |
| 42613422 | Global epidemiology of metabolic and alcohol-associated liver disease: risk factors, natural history and clinical implications. | Nat Rev Gastroenterol Hepatol | 2026 | https://conductscience.org/library/papers/42613422 | PubMed |
| 42578314 | MAFLD/MASLD: Past, Present, and Future. | J Gastroenterol Hepatol | 2026 | https://conductscience.org/library/papers/42578314 | PubMed |
| 42511850 | Circulating Adipokines in Alcohol-Related Liver Disease and MetALD: A Systematic Review and Structured Narrative Synthesis. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42511850 | PubMed |
| 42475412 | Therapeutics for Alcohol-Associated Liver Disease. | Annu Rev Pharmacol Toxicol | 2026 | https://conductscience.org/library/papers/42475412 | PubMed |
| 42414592 | Advancing liver health in a shifting global landscape. | Nat Rev Gastroenterol Hepatol | 2026 | https://conductscience.org/library/papers/42414592 | PubMed |
| 42156626 | Clinical trial endpoints for metabolic dysfunction and alcohol associated steatotic liver disease. | Hepatol Int | 2026 | https://conductscience.org/library/papers/42156626 | PubMed |
| 42120953 | Subtype Differences in Major Adverse Liver Outcomes and Cardiovascular Events and Mortality in Steatotic Liver Disease: A UK Biobank Analysis. | Aliment Pharmacol Ther | 2026 | https://conductscience.org/library/papers/42120953 | PubMed |
| 42044878 | Predictive modeling and clinical decision tools for risk stratification in steatotic liver disease. | Clin Mol Hepatol | 2026 | https://conductscience.org/library/papers/42044878 | PubMed |
| 41899181 | Alcohol Abstinence Is Associated with Regression of Non-Invasive Fibrosis Markers in Patients with Metabolic Syndrome: A 12-Month Prospective Study. | J Clin Med | 2026 | https://conductscience.org/library/papers/41899181 | PubMed |
| 41851447 | Therapeutic targets for metabolic dysfunction-associated steatohepatitis: a personalized approach to disease management. | Nat Rev Gastroenterol Hepatol | 2026 | https://conductscience.org/library/papers/41851447 | PubMed |
| 41596657 | Molecular and Regenerative Effects of Platelet-Rich Plasma and Related Hemocomponents in Animal Models of Liver Injury-A Systematic Review. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41596657 | PubMed |
| 41459093 | Metabolic dysfunction and alcohol-associated liver disease (MetALD). | eGastroenterology | 2025 | https://conductscience.org/library/papers/41459093 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41006824
GET https://conductscience.org/api/papers/v1/41006824/authors?page=2